Information Provided By:
Fly News Breaks for July 29, 2015
TRIB
Jul 29, 2015 | 07:42 EDT
Stephens attributes Trinity Biotech's Q2 miss to HIV and Lyme Disease testing, but said their "lumpiness" is not unexpected and that the company still has organic growth acceleration, margin expansion and the Troponin/BNP submission ahead of it. Stephens sees the recent weakness in the stock as an "excellent" opportunity and maintains its Overweight rating and $22 price target on Trinity shares.
News For TRIB From the Last 2 Days
There are no results for your query TRIB